Colonic Neoplasms, Drug Therapy
Conditions
Brief summary
To evaluate the efficacy and safety of neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) in the patients with locally advanced colon cancer.
Detailed description
For the patients with locally advanced colon cancer, adjuvant FOLFOX and XELOX chemotherapy have become standard treatment. However, 30% - 40% patients suffered from local recurrence or distant metastasis after this standard treatment. Neoadjuvant chemotherapy could shrink tumors, eliminate micrometastasis, reduce surgical trauma and accelerate recovery. Hence, we evaluate the efficacy and safety of FOLFOXIRI as neoadjuvant chemotherapy in treating patients with locally advanced colon cancer. In this prospective study, 30 patients with locally advanced colon cancer will be treated with 4 cycles of neoadjuvant FOLFOXIRI chemotherapy followed by surgical resection. PET-CT scanning will be performed before and after the neoadjuvant FOLFOXIRI chemotherapy to assess SUVmax changes. The ctDNA in peripheral blood before and after each cycle of neoadjuvant FOLFOXIRI chemotherapy will be detected. In the course of treatment, safety evaluation will be carried out according to adverse reaction classification (CTCAE) 4. 0.
Interventions
DRUGFOLFOXIRI
Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
Sponsors
China Medical University, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age: 18-75years old * Primary and pathological diagnosis of colon adenocarcinoma * Radiographic evaluation of initial resectable colon cancer * T4b colon cancer * ECOG status: 0～1 * Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×10\^9/L Platelet count≥90×10\^9/L Hemoglobin≥90g/L Total bilirubin (TBI) ≤ 1.5 \* ULN Alanine aminotransferase (ALT)≤2.5 \* ULN Aspartate aminotransferase (AST)≤2.5 \* ULN Alkaline phosphatase (ALP)≤2.5 \* ULN * Signed informed consent; able to comply with study and/or follow- up procedures
Exclusion criteria
* Previous treatment with oxaliplatin, irinotecan or fluorouracil * Hypersensitivity to fluorouracil, oxaliplatin or irinotecan. * With distant metastasis * Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia uncontrolled hypertension. Unexplained syncope occurred within 3 months * Digestive system diseases that would preclude study treatment or follow-up within the past 6 months * Gastric ulcers or duodenal ulcers for the treatment of resistance; * 3 or 4 grade gastrointestinal bleeding / bleeding; * Gastrointestinal perforation / fistula; * abdominal abscess; * Infectious or inflammatory bowel disease * HIV infection and/or active hepatitis B virus infection * Pregnant or lactating women. Fertile patients must use effective contraception * Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study * Other intervention clinical trials were combined at the same time. * Nerve or mental abnormality affecting cognitive ability * Other malignancy except effectively treated squamous cell or basal cell skin cancer, * Other situations that the researchers think should be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The ratio of tumor downstaging to stage 0 and stage I | 2 years | Tumor downstaging from stage II or III to pathologic complete response (stage 0) and stage I |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival | 3 years | Estimated from the date of surgery to the date of recurrence |
| Overall survival time | 3 years | Estimated from the date of enrollment to death from any cause |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 3 years | The grade of toxicity will be assessed using the NCI-CTCAE version 4.0 |
| Tumor regression grade (TRG) | 2 years | The level of tumor regression under pathological examination |
| SUVmax changes | At the begin of Cycle 1 and the end of Cycle 4 (each cycle is 14 days) | Tumor metabolic response through FDG-PET examination before and after 4 cycles of neoadjuvant FOLFOXIRI chemotherapy |
| Quality of life (QLQ C30) | Every 2 weeks after the first treatment until 3 years | Scores according to EORTC QLQ-C30 scoring manual |
| ctDNA change | 3 years | The relationship between ctDNA and survival will be evaluated |
Countries
China
Contacts
Primary ContactJingdong Zhang
Outcome results
None listed